DM Clinical Research is celebrating its 20th anniversary, marking two decades of expanding access to clinical trials and accelerating the development of innovative therapies across the United States. Founded in 2006 with a vision to make clinical research more accessible and patient-centered, the organization has grown into one of the nation's leading integrated clinical research networks, according to a company announcement.
Over the past two decades, DM Clinical Research has expanded its national footprint, therapeutic expertise, and research capabilities. Today, it operates more than 35 research sites and provides access to a patient population of 1.97 million individuals across 32 therapeutic areas. The company has enrolled more than 35,000 patients in clinical trials, contributing to the advancement of safe, life-changing therapies worldwide.
The anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork and dedication that have fueled the organization's growth. Mohammad Millwala, founder and CEO, emphasized the importance of the people behind the milestone. "Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey," he said.
DM Clinical Research partners with leading pharmaceutical, biotechnology, and healthcare organizations, as well as contract research organizations (CROs), to conduct high-quality clinical trials. The company focuses on strong enrollment performance, diverse patient access, and operational excellence. As part of its mission, DM Clinical continues to grow its presence in underserved communities, ensuring more patients have the opportunity to participate in trials that could change their lives. Its integrated operating model combines local physician relationships with centralized infrastructure to deliver quality and speed for sponsors and CRO partners.
The company's commitment to excellence has been recognized with industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, Millwala received the SCRS Christine K. Pierre Site Impact Award for his leadership.
Looking ahead, DM Clinical Research plans to continue expanding into new communities, broaden its therapeutic expertise, and invest in innovative technologies to improve patient access to clinical research. "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives," Millwala added.
